Patients who stop using weight loss medications are likely to return to their baseline weight within two years, a new ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

Stocks closed solidly higher on Friday, pushing major indexes to big weekly gains for the third time in the last four weeks.

The U.S. is slashing funding for scientific research, after decades of deep investment. Here’s some of what those taxpayer dollars created.

The boss of Ozempic maker Novo Nordisk lost his job yesterday after its share price plunged amid intensifying competition in the multi-billion pound fat jab market. Lars Fruergaard Jorgensen is being ...

A growing number of users say Ozempic is rewiring their taste buds in ways they never saw coming. Many have complained about unexpected side effects like the Ozempic butt, the Ozempic mouth, and the ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

Over Lars Fruergaard Jørgensen's eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through ...

U.S.-listed shares of Novo Nordisk declined in the opening minutes of trading Friday on the surprise news that CEO Lars ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...